Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment of venous and arterial thromboembolism show promising results. A major disadvantage of these anticoagulants is the absence of an ant...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) Jg. 124; H. 14; S. 1573
Hauptverfasser:	Eerenberg, Elise S, Kamphuisen, Pieter W, Sijpkens, Meertien K, Meijers, Joost C, Buller, Harry R, Levi, Marcel
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 04.10.2011
Schlagworte:	Adult Anticoagulants - antagonists & inhibitors Antidotes - pharmacology Benzimidazoles - antagonists & inhibitors beta-Alanine - analogs & derivatives beta-Alanine - antagonists & inhibitors Blood Coagulation - drug effects Blood Coagulation Factors - pharmacology Cross-Over Studies Dabigatran Double-Blind Method Endopeptidases Factor Xa Inhibitors Humans Male Morpholines - antagonists & inhibitors Partial Thromboplastin Time Prothrombin Time Rivaroxaban Thiophenes - antagonists & inhibitors Thrombin - antagonists & inhibitors Thrombin Time Young Adult
ISSN:	1524-4539, 1524-4539
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!